What do we Mean by “Ideal” Blood Pressure Control?

Arterial hypertension (AH) is one of the most important risk factors for development of myocardial infarction, chronic heart failure, stroke, cognitive disorders and dementia, and chronic kidney disease. Currently, special attention is paid to increased blood pressure variability (BPV) as a new risk factor for development of cardiovascular and cerebrovascular complications. The available evidence-based body of clinical studies demonstrates the importance of reducing not only the blood pressure itself but also the increased BPV to provide significant improvement of the prognosis and limits the risk of complications. This notion has been validated in consensus documents on the management of patients with AH. Among antihypertensive drugs, the fixed-dose combination (FC) amlodipine/perindopril has demonstrated a unique capability for reducing all types of BPV (visit-to-visit, day-to-day, during 24 h). According to current clinical guidelines, this combination belongs to first-line FCs indicated for most patients with AH. A distinctive feature of the FC amlodipine/perindopril is numerous data from real-life clinical practice, which support both its high antihypertensive efficacy and the ability to decrease high BPV. Therefore, the FC amlodipine/perindopril can be recommended for a broad range of AH patients to achieve BP control and to improve the prognosis.

1. Ministry of Health of Russian Federation. Clinical guidelines. Arterial hypertension in adults. KR62. 2020. http://cr.rosminzdrav.ru/#!/schema/687]

2. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021–104. DOI: 10.1093/eurheartj/ehy339

3. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. The Lancet. 2002;360(9349):1903–13. PMID: 12493255

4. Psaty BM, Furberg CD, Kuller LH, Cushman M, Savage PJ, Levine D et al. Association Between Blood Pressure Level and the Risk of Myocardial Infarction, Stroke, and Total Mortality: The Cardiovascular Health Study. Archives of Internal Medicine. 2001;161(9):1183–92. DOI: 10.1001/archinte.161.9.1183

5. Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet. 2004;364(9438):937–52. DOI: 10.1016/S0140-6736(04)17018-9

6. Donkor ES. Stroke in the 21 st Century: A Snapshot of the Burden, Epidemiology, and Quality of Life. Stroke Research and Treatment. 2018;2018:3238165. DOI: 10.1155/2018/3238165

7. Wajngarten M, Silva GS. Hypertension and Stroke: Update on Treatment. European Cardiology Review. 2019;14(2):111–5. DOI: 10.15420/ecr.2019.11.1

8. Guzik A, Bushnell C. Stroke Epidemiology and Risk Factor Management. CONTINUUM: Lifelong Learning in Neurology. 2017;23(1):15–39. DOI: 10.1212/CON.0000000000000416

9. Béjot Y. Targeting blood pressure for stroke prevention: current evidence and unanswered questions. Journal of Neurology. 2021;268(3):785–95. DOI: 10.1007/s00415-019-09443-5

10. Seshadri S, Wolf PA, Beiser A, Vasan RS, Wilson PWF, Kase CS et al. Elevated Midlife Blood Pressure Increases Stroke Risk in Elderly Persons: The Framingham Study. Archives of Internal Medicine. 2001;161(19):2343–50. DOI: 10.1001/archinte.161.19.2343

11. Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy lifeyears lost, and age-specific associations in 1·25 million people. The Lancet. 2014;383(9932):1899–911. DOI: 10.1016/S0140-6736(14)60685-1

12. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D’Agostino RB, Kannel WB et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106(24):3068–72

13. Málek F. Arterial hypertension and chronic heart failure. Cor et Vasa. 2013;55(3):e259–63. DOI: 10.1016/j.crvasa.2013.04.002

14. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR et al. Midlife blood pressure and dementia: the Honolulu–Asia aging study. Neurobiology of Aging. 2000;21(1):49–55. DOI: 10.1016/S0197-4580(00)00096-8

15. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005;64(2):277–81. DOI: 10.1212/01.WNL.0000149519.47454.F2

16. Gottesman RF, Schneider ALC, Albert M, Alonso A, BandeenRoche K, Coker L et al. Midlife Hypertension and 20-Year Cognitive Change: The Atherosclerosis Risk in Communities Neurocognitive Study. JAMA Neurology. 2014;71(10):1218–27. DOI: 10.1001/jamaneurol.2014.1646

17. Garofalo C, Borrelli S, Pacilio M, Minutolo R, Chiodini P, De Nicola L et al. Hypertension and Prehypertension and Prediction of Development of Decreased Estimated GFR in the General Population: A Meta-analysis of Cohort Studies. American Journal of Kidney Diseases. 2016;67(1):89–97. DOI: 10.1053/j.ajkd.2015.08.027

18. Reynolds K, Gu D, Muntner P, Kusek JW, Chen J, Wu X et al. A Population-Based, Prospective Study of Blood Pressure and Risk for End-Stage Renal Disease in China. Journal of the American Society of Nephrology. 2007;18(6):1928–35. DOI: 10.1681/ASN.2006111199

19. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. The Lancet. 2016;387(10022):957–67. DOI: 10.1016/S0140-6736(15)01225-8

20. Levi Marpillat N, Macquin-Mavier I, Tropeano A-I, BachoudLevi A-C, Maison P. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. Journal of Hypertension. 2013;31(6):1073–82. DOI: 10.1097/HJH.0b013e3283603f53

21. Lv J, Ehteshami P, Sarnak MJ, Tighiouart H, Jun M, Ninomiya T et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. Canadian Medical Association Journal. 2013;185(11):949–57. DOI: 10.1503/cmaj.121468

22. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE et al. Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis. Annals of Internal Medicine. 2003;139(4):244–52. DOI: 10.7326/0003-4819-139-4-200308190-00006

23. Gorbunov V.M. Modern views on the variability of blood pressure. Rational Pharmacotherapy in Cardiology. 2012;8(6):810–8. DOI: 10.20996/1819-6446-2012-8-6-810-818

24. Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlöf B et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. The Lancet. 2010;375(9718):895–905. DOI: 10.1016/S0140-6736(10)60308-X

25. Höcht C. Blood Pressure Variability: Prognostic Value and Therapeutic Implications. ISRN Hypertension. 2013;2013:398485. DOI: 10.5402/2013/398485

26. Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G. Relationship of 24-Hour Blood Pressure Mean and Variability to Severity of Target-Organ Damage in Hypertension. Journal of Hypertension. 1987;5(1):93–8. DOI: 10.1097/00004872-198702000-00013

27. Mancia G, Parati G, Hennig M, Flatau B, Omboni S, Glavina F et al. Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension. 2001;19(11):1981–9. DOI: 10.1097/00004872-200111000-00008

28. Sega R, Corrao G, Bombelli M, Beltrame L, Facchetti R, Grassi G et al. Blood Pressure Variability and Organ Damage in a General Population: Results from the PAMELA Study. Hypertension. 2002;39(2):710–4. DOI: 10.1161/hy0202.104376

29. McMullan CJ, Bakris GL, Phillips RA, Forman JP. Association of BP Variability with Mortality among African Americans with CKD. Clinical Journal of the American Society of Nephrology. 2013;8(5):731–8. DOI: 10.2215/CJN.10131012

30. Kawai T, Ohishi M, Kamide K, Nakama C, Onishi M, Ito N et al. Differences between daytime and nighttime blood pressure variability regarding systemic atherosclerotic change and renal function. Hypertension Research. 2013;36(3):232–9. DOI: 10.1038/hr.2012.162

31. Schillaci G, Bilo G, Pucci G, Laurent S, Macquin-Mavier I, Boutouyrie P et al. Relationship Between Short-Term Blood Pressure Variability and Large-Artery Stiffness in Human Hypertension: Findings From 2 Large Databases. Hypertension. 2012;60(2):369–77. DOI: 10.1161/HYPERTENSIONAHA.112.197491

32. Schutte AE, Schutte R, Huisman HW, van Rooyen JM, Fourie CM, Malan NT et al. Blood pressure variability is significantly associated with ECG left ventricular mass in normotensive Africans: The SABPA Study. Hypertension Research. 2011;34(10):1127–34. DOI: 10.1038/hr.2011.104

33. Sakakura K, Ishikawa J, Okuno M, Shimada K, Kario K. Exaggerated Ambulatory Blood Pressure Variability Is Associated with Cognitive Dysfunction in the Very Elderly and Quality of Life in the Younger Elderly. American Journal of Hypertension. 2007;20(7):720–7. DOI: 10.1016/j.amjhyper.2007.02.001

34. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the AngloScandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. The Lancet. 2005;366(9489):895–906. DOI: 10.1016/S0140-6736(05)67185-1

35. Parati G, Ulian L, Santucciu C, Omboni S, Mancia G. Blood pressure variability, cardiovascular risk and antihypertensive treatment. Journal of Hypertension. 1995;13(Suppl 4):S27–34. DOI: 10.1097/00004872-199512002-00005

36. Frattola A, Parati G, Cuspidi C, Albini F, Mancia G. Prognostic value of 24-hour blood pressure variability. Journal of Hypertension. 1993;11(10):1133–7. DOI: 10.1097/00004872-199310000-00019

37. Verdecchia P, Angeli F, Gattobigio R, Rapicetta C, Reboldi G. Impact of Blood Pressure Variability on Cardiac and Cerebrovascular Complications in Hypertension. American Journal of Hypertension. 2007;20(2):154–61. DOI: 10.1016/j.amjhyper.2006.07.017

38. Ostroumova O.D., Borisova E.V., Pavleeva E.E. Blood Pressure Variability. Visit-to-Visit Blood Pressure Variability. Kardiologiia. 2017;57(11):68–75. DOI: 10.18087/cardio.2017.11.10056

39. Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlöf B et al. Effects of β-blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. The Lancet Neurology. 2010;9(5):469–80. DOI: 10.1016/S1474-4422(10)70066-1

40. Diaz KM, Tanner RM, Falzon L, Levitan EB, Reynolds K, Shimbo D et al. Visit-to-Visit Variability of Blood Pressure and Cardiovascular Disease and All-Cause Mortality: A Systematic Review and Meta-Analysis. Hypertension. 2014;64(5):965–82. DOI: 10.1161/HYPERTENSIONAHA.114.03903

41. Mancia G, Bombelli M, Facchetti R, Madotto F, Corrao G, Trevano FQ et al. Long-Term Prognostic Value of Blood Pressure Variability in the General Population: Results of the Pressioni Arteriose Monitorate e Loro Associazioni Study. Hypertension. 2007;49(6):1265–70. DOI: 10.1161/HYPERTENSIONAHA.107.088708

42. Mena LJ, Maestre GE, Hansen TW, Thijs L, Liu Y, Boggia J et al. How Many Measurements Are Needed to Estimate Blood Pressure Variability Without Loss of Prognostic Information? American Journal of Hypertension. 2014;27(1):46–55. DOI: 10.1093/ajh/hpt142

43. Gosmanova EO, Mikkelsen MK, Molnar MZ, Lu JL, Yessayan LT, Kalantar-Zadeh K et al. Association of Systolic Blood Pressure Variability With Mortality, Coronary Heart Disease, Stroke, and Renal Disease. Journal of the American College of Cardiology. 2016;68(13):1375–86. DOI: 10.1016/j.jacc.2016.06.054

44. Wang Q, Wang Y, Wang J, Zhang L, Zhao M, Wang X et al. Short‐ Term Systolic Blood Pressure Variability and Kidney Disease Progression in Patients With Chronic Kidney Disease: Results From C‐STRIDE. Journal of the American Heart Association. 2020;9(12):e015359. DOI: 10.1161/JAHA.120.015359

45. Yoo JE, Shin DW, Han K, Kim D, Lee S-P, Jeong S-M et al. Blood Pressure Variability and the Risk of Dementia: A Nationwide Cohort Study. Hypertension. 2020;75(4):982–90. DOI: 10.1161/HYPERTENSIONAHA.119.14033

46. Ma Y, Wolters FJ, Chibnik LB, Licher S, Ikram MA, Hofman A et al. Variation in blood pressure and long-term risk of dementia: A population-based cohort study. PLOS Medicine. 2019;16(11):e1002933. DOI: 10.1371/journal.pmed.1002933

47. Rouch L, Vidal J-S, Hoang T, Cestac P, Hanon O, Yaffe K. Systolic blood pressure postural changes variability is associated with greater dementia risk. Neurology. 2020;95(14):e1932–40. DOI: 10.1212/WNL.0000000000010420

48. Tully PJ, Dartigues J-F, Debette S, Helmer C, Artero S, Tzourio C. Dementia risk with antihypertensive use and blood pressure variability: A cohort study. Neurology. 2016;87(6):601–8. DOI: 10.1212/WNL.0000000000002946

49. Kobalava Zh.D., Konradi A.O., Nedogoda S.V., Arutyunov G.P., Baranova E.I., Barbarash O.L. et al. Russian Society of Cardiology position paper on 2018 Guidelines of the European Society of Cardiology/European Society of Arterial Hypertension for the management of arterial hypertension. Russian Journal of Cardiology. 2018;23(12):131–42. DOI: 10.15829/1560-4071-2018-12-131-142

50. Zhang Y, Ly C, Yannoutsos A, Agnoletti D, Mourad J-J, Safar ME et al. Effect of a fixed combination of Perindopril and Amlodipine on blood pressure control in 6256 patients with not-at-goal hypertension: the AVANT’AGE study. Journal of the American Society of Hypertension. 2013;7(2):163–9. DOI: 10.1016/j.jash.2013.01.006

51. Hatala R, Pella D, Hatalová K, Šidlo R. Optimization of Blood Pressure Treatment with Fixed-Combination Perindopril/Amlodipine in Patients with Arterial Hypertension. Clinical Drug Investigation. 2012;32(9):603–12. DOI: 10.1007/BF03261915

52. Nagy VL. Twenty-Four-Hour Ambulatory Blood Pressure Reduction with a Perindopril/Amlodipine Fixed-Dose Combination. Clinical Drug Investigation. 2013;33(7):469–76. DOI: 10.1007/s40261-013-0086-9

53. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. The Lancet. 2010;375(9718):906–15. DOI: 10.1016/S0140-6736(10)60235-8

54. Ostroumova O.D. First results of the Russian database of international prospective observational registry variability of blood pressure in patients with hypertension. Systemic Hypertensions. 2014;11(4):9–16.

55. Kobalava Zh.D., Kotovskaya Yu.V., Lukyanova E.A. Combined Therapy of Arterial Hypertension With the Fixed Combination of Perindopril Arginine/Amlodipine in Real Clinical Practice: the Organization and the Main Results of the Program CONSTANTA. Kardiologiia. 2013;53(6):25–34.

56. Karpov Yu.A., Deev A.D. Uncontrolled arterial hypertension - new possibilities in solving problems of increasing the effectiveness of treatment. Kardiologiia. 2012;52(2):29–35.

57. Gorbunov V.M., Karpov Yu.A., Deev A.D. PRORYV 2 study: Part II. The effect of a fixed-dose combination of perindopril arginine/amlodipine on the variability of blood pressure and the quality of life of patients with initially uncontrolled arterial hypertension. Atmosphere. Cardiology News. 2014;2:3–10.